Matthew Wilde, MD

Biography

Dr. Matthew Wilde is an ophthalmologist and retina specialist who provides eye care services in Charlotte, NC and Pineville, NC. He specializes in the treatment of medical and surgical retinal diseases such as diabetic retinopathy, retinal vascular diseases, age-related macular degeneration, retinal detachments, secondary intraocular lens placements, macular holes and epiretinal membranes.

Graduating summa cum laude from Brigham Young University with a degree in exercise science, Dr. Wilde received his medical degree from the Medical University of South Carolina. After completing his internship and ophthalmology residency at the University of Florida, he finished his fellowship in vitreoretinal diseases and surgery at Retina & Vitreous of Texas in Houston where he was a sub-investigator in multiple clinical trials. Dr. Wilde is board certified by the American Academy of Ophthalmology.

Outside of the office, Dr. Wilde enjoys spending time with his wife and five kids, participating in outdoor activities, sports, and volunteering in his community.

Dr. Wilde practices in our SouthPark (6035 Fairview Road, Charlotte, NC), Blakeney (5933 Blakeney Park Drive, Suite 200, Charlotte, NC) and Pineville (10405 Centrum Parkway, Pineville, NC) offices. To make an appointment with him, you may do so online, through myCEENTAchart, or by calling 704-295-3000.

Education & Fellowship

Undergraduate
Brigham Young University, 2014

Medical
Medical University of South Carolina, 2018

Internship
Internal Medicine, University of Florida, 2019

Residency
Ophthalmology, University of Florida, 2022

Fellowship
Vitreoretinal Surgery, Retina & Vitreous of Texas, 2024

Associations & Memberships

• American Academy of Ophthalmology
• American Society of Retina Specialists

Research

Clinical Trials (sub-investigator)

Genentech Roche:
A Phase III, Multicenter, Randomized, Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy (Pavilion)
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema (Rhone-X)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (Balaton)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (Comino)
A Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naïve, Underrepresented Patients with Diabetic Macular Edema (Elevatum)
A Phase 1, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema
Iveric Bio:
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Gather2)

Presentations

“Choroidal Melanoma: Referral Patterns, Treatment Modalities, Clinical Outcomes and Cytogenetic-based Survival”. 2021 Resident Research Day, University of Florida Ophthalmology, June 2021